Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

HD11 for Intermediate Stages

Phase 3

Completed

Conditions: Hodgkin´s Lymphoma

Interventions: Drug: Adriamycin
Drug: Bleomycin
Drug: Vinblastine
Drug: Etoposide
Drug: DTIC
Drug: Procarbazine
Radiation: radiation therapy
Drug: Prednisone
Drug: Vincristine

First Posted Date: 2005-12-13

Last Posted Date: 2011-08-04

Lead Sponsor: University of Cologne

Target Recruit Count: 1395

Registration Number: NCT00264953

Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: carboplatin
Drug: etoposide
Drug: ifosfamide

First Posted Date: 2005-11-21

Last Posted Date: 2016-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 98

Registration Number: NCT00255723

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

Not Applicable

Terminated

Conditions: Myelodysplastic/Myeloproliferative Diseases
Lymphoma
Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Sarcoma
Chronic Myeloproliferative Disorders
Graft Versus Host Disease

First Posted Date: 2005-11-15

Last Posted Date: 2012-05-28

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 4

Registration Number: NCT00253552

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Biological: Filgrastim
Drug: Carboplatin
Drug: Etoposide
Drug: Melphalan
Procedure: Peripheral blood stem cell infusion
Radiation: 131I-MIBG
Radiation: Radiation therapy

First Posted Date: 2005-11-15

Last Posted Date: 2023-04-10

Lead Sponsor: Children's Hospital Los Angeles

Target Recruit Count: 50

Registration Number: NCT00253435

Locations: 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
University of Chicago Comer Children's Hospital, Chicago, Illinois, United States

and more 12 locations

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Phase 2

Terminated

Conditions: Non-Hodgkin's Lymphoma
Cancer

Interventions: Drug: Vincristine
Drug: VP-16
Drug: Rituximab
Drug: Dexamethasone
Drug: Levofloxacin

First Posted Date: 2005-11-08

Last Posted Date: 2015-08-03

Lead Sponsor: New Mexico Cancer Care Alliance

Target Recruit Count: 17

Registration Number: NCT00250718

Locations: 🇺🇸
University of New Mexico Cancer Center, Albuquerque, New Mexico, United States

Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: therapeutic autologous lymphocytes
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: peripheral blood stem cell transplantation (PBSCT)

First Posted Date: 2005-10-27

Last Posted Date: 2015-03-26

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00244946

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2005-10-21

Last Posted Date: 2017-09-28

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 44

Registration Number: NCT00242996

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2005-10-13

Last Posted Date: 2017-11-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 59

Registration Number: NCT00238368

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: carmustine
Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2005-10-06

Last Posted Date: 2018-03-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 98

Registration Number: NCT00233987

Locations: 🇺🇸
Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States
🇺🇸
Associates in Womens Health, PA - North Review, Wichita, Kansas, United States
🇺🇸
Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States

and more 50 locations

High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II

Phase 2

Completed

Conditions: Testicular Neoplasms

Interventions: Drug: epirubicin
Procedure: high-dose and autologous stem cell transplantation
Drug: paclitaxel
Drug: etoposide
Drug: ifosfamide
Drug: carboplatin

First Posted Date: 2005-10-04

Last Posted Date: 2011-02-25

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 50

Registration Number: NCT00231582

Locations: 🇫🇷
Hôpital TENON, Service d'Oncologie Médicale, Paris, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy